CClinicalTrials.gg
RecruitingNCT06943599Updated Apr 29, 2026

Strategies for Improving Linkage-to-Care After Eye Disease Screening

An interventional study of Text Message Reminder and Health Worker Visit in Age Related Macular Degeneration, Diabetic Retinopathy and Glaucoma, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
3,000
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

The goal of this randomized, parallel-group, controlled trial is to compare methods of improving linkage-to-care for participants in the Village Integrated Eye Worker II (VIEW II) trial who are referred to the eye hospital following eye disease screening. Participants who are referred to the hospital at an eye screening visit will be randomized to three different linkage-to-care interventions: (1) text message reminders, (2) reminders from health workers, or (3) no intervention. The primary outcome of the trial will be whether or not the participant presented to the eye hospital for a referral visit by 21 days following screening.

02

Conditions studied

  • Age Related Macular Degeneration
  • Diabetic Retinopathy
  • Glaucoma

Keywords

  • Eye Diseases
  • mass screening
  • patient compliance
  • retention in care
03

In context

Macular Degeneration

1,474 studies on the registry are indexed under Macular Degeneration; 206 are open to participants now.

This study's planned enrollment of 3,000 is above the median of 51 across 985 interventional studies indexed under Macular Degeneration.

Browse Macular Degeneration studies →

Lead sponsor

University of California, San Francisco is the lead sponsor of 2,132 studies on the registry; 375 are open to participants now.

Of its 262 completed or terminated interventional studies of FDA-regulated products, 196 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

- Participant of the VIEW II study referred to the eye hospital at their eye screening visit.

Exclusion criteria

Exclusion Criteria:

  • Residence in an area without reliable mobile connectivity
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
3,000 participants (estimated)

Study arms

  • Experimental
    Text Message Reminders

    Other: Text Message Reminder

  • Experimental
    Health Worker

    Other: Health Worker Visit

  • No intervention
    No Intervention

Interventions

  • OtherText Message Reminder

    Participants referred to the eye hospital after screening will receive a text message reminding them to attend their referral visit.

  • OtherHealth Worker Visit

    Participants referred to the eye hospital after screening will receive a home visit from a health worker reminding them to attend their referral visit.

06

What researchers measure

Primary outcomes

  1. Referral Visit Attendance

    The count of participants who attend the referral visit.

    Time frame: 21 days after screening

07

Study locations

1 of 1 sites recruiting
  • University of California, San Francisco
    San Francisco, California 94158, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data including age, cluster identifier, referral visit attendance

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06943599
Lead sponsor
University of California, San Francisco
Collaborators
Seva Foundation, National Eye Institute (NEI)
Responsible party
Sponsor
First posted
Apr 24, 2025
Start date
Feb 1, 2026
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Apr 29, 2026

Study contacts

Jeremy Keenan, MD, MPH
Contact
jeremy.keenan@ucsf.edu
(415) 476-1442
Krisianne Aromin
Contact
krisianne.aromin@ucsf.edu
Jeremy Keenan, MD, MPH
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion